Renowned scientist and entrepreneur Scott Rocklage is a rare breed. He has found success through boldly seeking out business ventures in his career. However, his background in the sciences allows him to take measured risk, either related to inventing a new patent or managing on his portfolio companies. Through education and leadership, Rocklage has found his niche in the healthcare investment market. Read more: Scott Racklage | Crunchbase
Throughout the years, Scott Rocklage has held numerous high-ranking positions at different companies. Rocklage was involved in research and development of new medications at multiple corporations, including Catalytica and Salutar.
He was also the President and CEO of Cubist Pharmaceuticals for a period of time, as well as serving on the board for Novira and Relypsa. Scott Rocklage was integral in the approval of three new medications by the FDA. His work included finding qualified candidates for clinical trials.
Scott Rocklage is now a Managing Partner of 5AM Ventures, a capital investment firm that specializes in growing other businesses in the area of life sciences.
Rocklage joined the 5AM team as a Venture Partner in 2003 and became a Managing partner only a year later. Currently, Rocklage is based out of the offices he runs in Boston, Massachusetts. He has over three decades of experience in the healthcare industry.
Prior to his career, Scott Rocklage attended the University of California at Berkeley. He graduated from UC Berkeley with a Bachelor of Science degree in Chemistry. Rocklage also attended the Massachusetts Institute of Technology. He completed his studies at MIT and was given his Ph.D. in Chemistry. Scott Rocklage regularly studies advances in research to expand his knowledge in his own free time. His specific focus is the area of life science.
Scott Rocklage has an impressive list of accomplishments in the scientific field. He has published over 100 technical articles that have been reviewed by peers. Rocklage was also the sole inventor or co-inventor behind more than 30 patents that are registered within the United States. His experience stems from performing research in the laboratory of Richard R Schrock, a recipient of the Nobel Prize for Chemistry in 2005.